AU7345794A - Pharmaceutical compositions for hardly soluble active substances - Google Patents

Pharmaceutical compositions for hardly soluble active substances

Info

Publication number
AU7345794A
AU7345794A AU73457/94A AU7345794A AU7345794A AU 7345794 A AU7345794 A AU 7345794A AU 73457/94 A AU73457/94 A AU 73457/94A AU 7345794 A AU7345794 A AU 7345794A AU 7345794 A AU7345794 A AU 7345794A
Authority
AU
Australia
Prior art keywords
active agent
component
pharmaceutical compositions
active substances
hardly soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU73457/94A
Other versions
AU689486B2 (en
Inventor
Ulrich Posanski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6492300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU7345794(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU7345794A publication Critical patent/AU7345794A/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Amend patent request/document other than specification (104) Assignors: SANDOZ LTD.
Application granted granted Critical
Publication of AU689486B2 publication Critical patent/AU689486B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pharmaceutical prepn. comprises () a pharmaceutically active agent which is sparingly soluble in water; and (b) a carrier compsn. comprising (i) at least one polyglycerine fatty acid ester and/or at least one sorbitan fatty acid ester, (ii) at least 1 conventional pharmaceutical oil contg. a triglyceride as lipophilic component and (iii) at least 1 nonionic surfactant with a HLB value of at least 10. The active agent is pref. a cyclosporin, rapamycin, tacrolimus, deoxyspergualine, nifedipine, nimodipine, etoposide, ibuprofen or alpha-lipoic acid. The active agent has a solubility, in distilled water, of less than 500mg/1000ml. The active agent concn. is 1-30 wt.%, based on the carrier compsn. The carrier compsn. comprises 10-50 wt.% component (i), 5-40 wt% component (ii) and 10-50 wt % component (iii).
AU73457/94A 1993-07-08 1994-07-08 Pharmaceutical compositions for hardly soluble active substances Expired AU689486B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4322826A DE4322826A1 (en) 1993-07-08 1993-07-08 Pharmaceutical preparation
DE4322826 1993-07-08
PCT/EP1994/002238 WO1995001785A1 (en) 1993-07-08 1994-07-08 Pharmaceutical compositions for hardly soluble active substances

Publications (2)

Publication Number Publication Date
AU7345794A true AU7345794A (en) 1995-02-06
AU689486B2 AU689486B2 (en) 1998-04-02

Family

ID=6492300

Family Applications (2)

Application Number Title Priority Date Filing Date
AU73850/94A Abandoned AU7385094A (en) 1993-07-08 1994-07-08 Pharmaceutical compositions for hardly soluble active substances
AU73457/94A Expired AU689486B2 (en) 1993-07-08 1994-07-08 Pharmaceutical compositions for hardly soluble active substances

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU73850/94A Abandoned AU7385094A (en) 1993-07-08 1994-07-08 Pharmaceutical compositions for hardly soluble active substances

Country Status (24)

Country Link
EP (3) EP1092429B1 (en)
JP (4) JPH08512301A (en)
KR (2) KR100359044B1 (en)
CN (2) CN1121853C (en)
AT (3) ATE201985T1 (en)
AU (2) AU7385094A (en)
BR (1) BR9407002A (en)
CA (2) CA2166204C (en)
CY (2) CY2308B1 (en)
CZ (1) CZ291401B6 (en)
DE (6) DE4322826A1 (en)
DK (3) DK0710104T3 (en)
ES (3) ES2124420T3 (en)
FI (2) FI116197B (en)
GR (1) GR3036571T3 (en)
HU (2) HU223073B1 (en)
NO (2) NO306929B1 (en)
NZ (2) NZ269808A (en)
PL (1) PL179717B1 (en)
PT (2) PT1092429E (en)
RU (1) RU2140291C1 (en)
SI (1) SI1092429T1 (en)
SK (1) SK280615B6 (en)
WO (2) WO1995001785A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6696413B2 (en) * 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
GB2317562B (en) * 1995-07-20 1999-08-18 Danbiosyst Uk Lipid vehicle drug delivery composition containing vitamin E
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
DE19544507B4 (en) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
EP0978288A4 (en) * 1997-04-11 2006-07-12 Astellas Pharma Inc Medicinal composition
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
DE60016617T2 (en) * 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills NON-ADVENTURES BELLY SOAP CAPSULES
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
CN100453079C (en) * 2000-11-24 2009-01-21 润风美有限公司 Water-soluble liquid internal medicine
DE10161077A1 (en) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions for needleless injection
EP1455810B1 (en) 2001-12-14 2007-06-13 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
KR100533458B1 (en) * 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1603560A1 (en) 2003-02-06 2005-12-14 Cipla Ltd. Topical immunotherapy and compositions for use therein
JPWO2004073692A1 (en) * 2003-02-18 2006-06-01 山下　伸二 Hard capsule of poorly water-soluble drug
ES2592504T3 (en) * 2003-07-17 2016-11-30 Banner Life Sciences, LLC Controlled release preparations
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
GB0425255D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Pharmaceutical composition
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070196465A1 (en) * 2005-07-28 2007-08-23 George Bobotas Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
PT2117521E (en) 2006-11-03 2012-09-10 Durect Corp Transdermal delivery systems comprising bupivacaine
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
ITMI20070720A1 (en) * 2007-04-06 2008-10-07 Monteresearch Srl ORAL COMPOSITIONS CONTAINING TACROLIMUS IN AMORPHOUS FORM
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2965763B8 (en) * 2009-04-10 2018-08-15 Haiyan Qi Anti-aging agents
WO2011046853A1 (en) 2009-10-12 2011-04-21 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
SG183846A1 (en) 2010-03-03 2012-10-30 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP5970224B2 (en) 2011-07-11 2016-08-17 株式会社日本自動車部品総合研究所 Spark plug for internal combustion engine
KR20140071913A (en) * 2012-12-04 2014-06-12 삼성정밀화학 주식회사 Food composition and soft capsule including the same
BR112015025347A2 (en) * 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
KR20170102223A (en) * 2014-11-07 2017-09-08 시그모이드 파마 리미티드 Compositions comprising cyclosporin
WO2016078481A1 (en) 2014-11-21 2016-05-26 杭州领业医药科技有限公司 Pharmaceutical composition comprising tacrolimus and preparation method thereof
HRP20211488T1 (en) 2016-04-20 2022-02-18 Veroscience Llc Composition and method for treating metabolic disorders
JP2020503269A (en) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド Oral testosterone undecanoate therapy
EP4233913A3 (en) 2017-10-18 2023-10-18 VeroScience LLC Improved bromocriptine formulations
KR20200139138A (en) * 2018-03-14 2020-12-11 칸디 테라퓨틱스 리미티드 Novel pharmaceutical formulations containing dual NK-1/NK-3 receptor antagonists
CN108853044B (en) * 2018-07-06 2020-11-06 郑州明泽医药科技有限公司 Nifedipine sustained release tablet and preparation method thereof
CN115666621A (en) 2020-01-13 2023-01-31 度勒科特公司 Sustained release drug delivery systems with reduced impurities and related methods
WO2022131656A1 (en) * 2020-12-15 2022-06-23 윤관식 Alkaloid-containing, water-soluble emulsified composition
KR102583074B1 (en) * 2021-01-25 2023-09-25 윤관식 Water-soluble emulsion composition comprising natural polyphenolic compound
KR102524312B1 (en) * 2020-12-15 2023-04-21 윤관식 Water-soluble emulsion composition comprising ecdysteroid
CN113041236B (en) * 2021-03-23 2023-03-10 广州新济药业科技有限公司 Flurbiprofen cataplasm and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1132518A (en) * 1965-02-18 1968-11-06 Richardson Merrell Inc Medicinal composition
IT1090703B (en) * 1976-12-03 1985-06-26 Scherer Ltd R P IMPROVEMENT IN USEFUL COMPOSITIONS SUCH AS DRUG VEHICLES
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
KR0148748B1 (en) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 A multiphase cyclosporin composition
JPH0832638B2 (en) * 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
JPH0525037A (en) * 1991-07-01 1993-02-02 Upjohn Co:The Oral administrative enzyme sensitive enteric coating
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation

Also Published As

Publication number Publication date
CN1128495A (en) 1996-08-07
FI960042A0 (en) 1996-01-04
DE4322826A1 (en) 1995-01-12
EP0710103A1 (en) 1996-05-08
CN1313154C (en) 2007-05-02
NO960069L (en) 1996-01-05
CY2308B1 (en) 2003-11-14
ATE261720T1 (en) 2004-04-15
GR3036571T3 (en) 2001-12-31
CN1496743A (en) 2004-05-19
DE59407239D1 (en) 1998-12-10
KR100359044B1 (en) 2003-02-05
KR100386533B1 (en) 2003-08-21
JP2009138008A (en) 2009-06-25
EP1092429B1 (en) 2004-03-17
CZ4596A3 (en) 1996-04-17
PL312255A1 (en) 1996-04-01
WO1995001786A1 (en) 1995-01-19
FI116197B (en) 2005-10-14
PT1092429E (en) 2004-08-31
PT710103E (en) 2001-11-30
EP0710104B1 (en) 1998-11-04
NO960062L (en) 1996-01-05
WO1995001785A1 (en) 1995-01-19
SI1092429T1 (en) 2004-08-31
DK0710103T3 (en) 2001-09-24
AU7385094A (en) 1995-02-06
JPH08512301A (en) 1996-12-24
DE59409787D1 (en) 2001-07-19
RU2140291C1 (en) 1999-10-27
JP2011153150A (en) 2011-08-11
NO306929B1 (en) 2000-01-17
CZ291401B6 (en) 2003-03-12
FI960032A (en) 1996-02-09
DE4494850D2 (en) 1996-08-22
JPH08512303A (en) 1996-12-24
HU9503965D0 (en) 1996-03-28
EP0710104A1 (en) 1996-05-08
DK1092429T3 (en) 2004-07-19
CA2164100A1 (en) 1995-01-19
NZ269552A (en) 1996-07-26
HUT73427A (en) 1996-07-29
EP1092429A1 (en) 2001-04-18
ES2124420T3 (en) 1999-02-01
ATE201985T1 (en) 2001-06-15
BR9407002A (en) 1996-09-03
CY2604B2 (en) 2010-04-28
PL179717B1 (en) 2000-10-31
FI116714B (en) 2006-02-15
FI960032A0 (en) 1996-01-03
ATE172876T1 (en) 1998-11-15
SK1996A3 (en) 1997-04-09
NO306763B1 (en) 1999-12-20
HUT73661A (en) 1996-09-30
DE4494851D2 (en) 1996-12-19
DK0710104T3 (en) 1999-07-19
HU9503868D0 (en) 1996-02-28
FI960042A (en) 1996-01-04
CN1121853C (en) 2003-09-24
DE59410365D1 (en) 2004-04-22
ES2218046T3 (en) 2004-11-16
NO960069D0 (en) 1996-01-05
CA2166204A1 (en) 1995-01-19
HU223073B1 (en) 2004-03-01
SK280615B6 (en) 2000-05-16
ES2159564T3 (en) 2001-10-16
NZ269808A (en) 1996-07-26
HU228127B1 (en) 2012-12-28
CA2166204C (en) 2009-04-14
AU689486B2 (en) 1998-04-02
NO960062D0 (en) 1996-01-05
EP0710103B1 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
AU7345794A (en) Pharmaceutical compositions for hardly soluble active substances
TR199500299A2 (en) Pharmaceutical compositions.
SI0999826T1 (en) Self-emulsifying formulation for lipophilic compounds
KR960033448A (en) Docosahexaenoic acid (DHA) -containing aqueous solution composition
KR960033453A (en) Vitamin E Formulations